Pembrolizumab plus lenvatinib and belzutifan for specified solid tumors
What is the Purpose of this Study?
What is the Condition Being Studied?
Who Can Participate in this Study?
Age Group
Adults
Participating Institutions
What is Involved?
Study Details
Full Title
[MK-6482-016] An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors
Principal Investigator
Contacts
Gastrointestinal Oncology DCI Clinical Research Team
Email: gi-oncology-cru@dm.duke.edu
Phone: +1 919-668-1861
Protocol Number
IRB:
PRO00108150
NCT:
NCT04976634
ClinicalTrials.gov
View on ClinicalTrials.gov